Sökning: onr:"swepub:oai:DiVA.org:umu-9362" >
Well-being at onset...
Well-being at onset of hormone replacement therapy : comparison between two continuous combined regimens
-
- Ödmark, Inga-Stina, 1948- (författare)
- Umeå universitet,Obstetrik och gynekologi
-
- Bäckström, Torbjörn (författare)
- Umeå universitet,Obstetrik och gynekologi
-
- Jonsson, B (författare)
- Uppsala universitet,Institutionen för kvinnors och barns hälsa,Barnendokrinologisk forskning/Tuvemo
-
visa fler...
-
- Bixo, Marie (författare)
- Umeå universitet,Obstetrik och gynekologi
-
visa färre...
-
(creator_code:org_t)
- 2009-08-03
- 2004
- Engelska.
-
Ingår i: Climacteric. - : Informa UK Limited. - 1369-7137 .- 1473-0804. ; 7:1, s. 92-102
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives To compare the effect on well-being of two continuous combined hormone replacement therapies (HRTs) in women starting treatment (‘starters’) and women switching from mainly sequential HRT (‘switchers’). Methods This was a randomized, double-blind, 1-month trial, in which 249 postmenopausal women were treated with either conjugated estrogen plus medroxyprogesterone acetate (CE/MPA 0.625 mg/5 mg) or 17β-estradiol plus norethisterone acetate (E2/NETA 2 mg/1 mg) continuously. Twelve items for measuring climacteric symptoms and well-being were reported daily on a validated symptom scale. Results Women taking CE/MPA reported lower scores for breast tenderness (p = 0.005), depression (p = 0.019), irritability (p = 0.004) and tension (p = 0.048), compared with women taking E2/NETA. Compared with pretreatment, both groups developed side-effects during the first week: breast tenderness, swelling and depression (p < 0.05). Starters, but also switchers, improved in sweats (p < 0.001 and p = 0.030). Compared with pretreatment ratings, switchers reported higher scores for breast tenderness (p < 0.001), depression (p = 0.050) and negative effects on daily life (p < 0.001), whereas starters reported only physical side-effects (p < 0.05). A history of premenstrual syndrome (PMS) predicted high scores for swelling (p = 0.023), depression (p = 0.024), tension (p = 0.009), irritability (p = 0.027), headache (p < 0.001) and negative effects on daily life (p < 0.001). Conclusions CE/MPA 0.625 mg/5 mg is better tolerated than E2/NETA 2 mg/1 mg, and starters react differently from switchers. Side-effects occur more quickly than benefits with HRT, and are more frequent in women with previous PMS.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Nyckelord
- breast/physiopathology
- contraceptive Agents
- female/therapeutic use
- depression/drug therapy/psychology
- double-Blind method
- edema/physiopathology
- estrogen replacement therapy/*methods
- estrogens/therapeutic use
- estrogens
- conjugated (USP)/therapeutic use
- female
- humans
- irritable mood
- medroxyprogesterone 17-acetate/therapeutic use
- middle aged
- norethindrone/*analogs & derivatives/therapeutic use
- pain/physiopathology
- postmenopause/physiology/*psychology
- predictive value of tests
- prospective studies
- quality of life
- sleep initiation and maintenance disorders/drug therapy/psychology
- sweating/drug effects/physiology
- Obstetrics and gynaecology
- Obstetrik och gynekologi
- obstetrik och gynekologi
- Obstetrics and Gynaecology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas